TY - JOUR T1 - Longitudinal serology in SARS-CoV-2 infected individuals in India – a prospective cohort study JF - medRxiv DO - 10.1101/2021.02.04.21251140 SP - 2021.02.04.21251140 AU - Ramachandran Thiruvengadam AU - Souvick Chattopadhyay AU - Farha Mehdi AU - Bapu Koundinya Desiraju AU - Susmita Chaudhuri AU - Savita Singh AU - Vandita Bhartia AU - Pallavi Kshetrapal AU - Uma Chandra Mouli Natchu AU - Nitya Wadhwa AU - Shailaja Sopory AU - Mudita Wahi AU - Anil K. Pandey AU - Asim Das AU - Nidhi Anand AU - Nandini Sharma AU - Pragya Sharma AU - Sonal Saxena AU - Deepa Sindhu AU - Brahmdeep Sindhu AU - Dharmendra Sharma AU - Navin Dang AU - Gaurav Batra AU - Gagandeep Kang AU - Shinjini Bhatnagar AU - for DBT India Consortium for COVID-19 Research Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/08/2021.02.04.21251140.abstract N2 - Clinical and epidemiological characteristics of SARS-CoV-2 infection are now widely available, but there are few data on longitudinal serology in large cohorts, particularly from low-and middle-income countries. We established an ongoing prospective cohort of 3840 SARS-CoV-2 RT-PCR positive individuals in the Delhi-National Capital Region of India, to document clinical and immunological characteristics during illness and convalescence. The IgG responses to the receptor binding domain (RBD) and nucleocapsid were assessed at 0-7, 10-28 days and 6-10 weeks after infection. The clinical predictors of seroconversion were identified by multivariable regression analysis. The seroconversion rates in the post-infection windows of 0–7 days, 10–28 days and 6–10 weeks were 46%, 84.7% and 85.3% respectively (n=782). The proportion with a serological response increased with severity of COVID-19 disease. All participants with severe disease, 89.6% with mild to moderate infection and 77.3% of asymptomatic participants had IgG antibodies to the RBD antigen. The threshold values in the nasopharyngeal viral RNA RT-PCR in a subset of asymptomatic and symptomatic seroconverters were comparable (p value: 0.48), with similar results among non-seroconverters (p value: 0.16) (n=169). This is the first report of longitudinal humoral immune responses to SARS-CoV-2 infection over a period of ten weeks from South Asia. The low seropositivity in asymptomatic participants and differences between assays highlight the importance of contextualizing the understanding of population serosurveys.Summary We measured anti-SARS-CoV-2 RBD and NC protein IgG in a multi-hospital-based prospective cohort from northern India up to ten weeks post-infection. The lower seroconversion rate among asymptomatic RT-PCR positive participants has public health significance particularly for interpreting community seroprevalence estimates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Department of Biotechnology, Government of India [BT/PR40401/BIOBANK/03/2020] and Ind-CEPI- Coalition for Epidemic Preparedness Innovations [102/IFD/SAN/5477/2018-2019].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institute Ethics Committees of all participating institutions. Translational Health Science and Technology Institute THS 1.8.1/ (91) dated 13th April 2020; ESIC Medical College Hospital, Faridabad 134/A/11/16/academics/mc/2016/133, dated 15th April 2020 and Loknayak Hospital, New Delhi e-approval dated: Apr 21, 2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data referred to in the manuscript will be available on request after peer-reviewed publication, upon request to the corresponding author ER -